Healthcare provider profile · identity verified

Lidia Mikolaenko

Family Practice · NESCONSET, NY · NPI 1497175228

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	340	104
Levothyroxine Sodium	Levothyroxine Sodium	171	53
Omeprazole	Omeprazole	167	57
Amlodipine Besylate	Amlodipine Besylate	153	55
Rosuvastatin Calcium	Rosuvastatin Calcium	152	58
Losartan Potassium	Losartan Potassium	146	45
Metoprolol Succinate	Metoprolol Succinate	137	47
Metformin Hcl	Metformin Hcl	116	35
Alprazolam	Alprazolam	113	39
Hydrochlorothiazide	Hydrochlorothiazide	113	43
Sertraline Hcl	Sertraline Hcl	103	26
Simvastatin	Simvastatin	98	27
Pantoprazole Sodium	Pantoprazole Sodium	83	29
Lisinopril	Lisinopril	81	32
Tamsulosin Hcl	Tamsulosin Hcl	71	23
Albuterol Sulfate Hfa	Albuterol Sulfate	66	36
Gabapentin	Gabapentin	66	26
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	64	52
Carvedilol	Carvedilol	62	22
Finasteride	Finasteride	62	18
Famotidine	Famotidine	60	14
Eliquis	Apixaban	58	21
Doxycycline Hyclate	Doxycycline Hyclate	57	50
Fluticasone Propionate	Fluticasone Propionate	55	26
Synthroid	Levothyroxine Sodium	51	17
Valsartan	Valsartan	51	16
Furosemide	Furosemide	49	18
Escitalopram Oxalate	Escitalopram Oxalate	47	14
Pravastatin Sodium	Pravastatin Sodium	46	18
Allopurinol	Allopurinol	43	15
Januvia	Sitagliptin Phosphate	42	13
Hydrocortisone	Hydrocortisone	40	21
Ezetimibe	Ezetimibe	39	12
Farxiga	Dapagliflozin Propanediol	39	suppressed
Clopidogrel	Clopidogrel Bisulfate	37	14
Cephalexin	Cephalexin	36	35
Montelukast Sodium	Montelukast Sodium	36	14
Azithromycin	Azithromycin	35	33
Irbesartan	Irbesartan	34	suppressed
Meloxicam	Meloxicam	34	16
Atenolol	Atenolol	33	12
Methylprednisolone	Methylprednisolone	33	32
Metoprolol Tartrate	Metoprolol Tartrate	33	suppressed
Mirtazapine	Mirtazapine	31	suppressed
Lactulose	Lactulose	30	suppressed
Metformin Hcl Er	Metformin Hcl	30	13
Duloxetine Hcl	Duloxetine Hcl	29	suppressed
Prednisone	Prednisone	29	22
Ramipril	Ramipril	29	suppressed
Torsemide	Torsemide	29	13
Donepezil Hcl	Donepezil Hcl	28	suppressed
Tramadol Hcl	Tramadol Hcl	28	13
Baclofen	Baclofen	27	suppressed
Meclizine Hcl	Meclizine Hcl	26	18
Ozempic	Semaglutide	26	suppressed
Potassium Chloride	Potassium Chloride	26	suppressed
Ketoconazole	Ketoconazole	24	14
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Enalapril Maleate	Enalapril Maleate	22	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	22	suppressed
Trazodone Hcl	Trazodone Hcl	22	14
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Azelastine Hcl	Azelastine Hcl	21	16
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	20	suppressed
Celecoxib	Celecoxib	20	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Diltiazem Hcl	Diltiazem Hcl	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Naproxen	Naproxen	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	11
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	16	suppressed
Glimepiride	Glimepiride	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	15	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	14	suppressed
Fluconazole	Fluconazole	14	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Galantamine Hbr	Galantamine Hbr	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	14	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	14	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	14	13
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Bupropion Hcl	Bupropion Hcl	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Eplerenone	Eplerenone	11	suppressed
Fesoterodine Fumarate Er	Fesoterodine Fumarate	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error